Several novel cytotoxic drugs in development and undergoing phase 2 and 3 trials may soon offer clinicians new treatment options for patients with metastatic breast cancer that is resistant or refractory to standard therapies.
http://www.docguide.com/news/content...C8B?Open&type=
Linear Mode
